NCT05468073View on ClinicalTrials.gov

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

Proleukin

Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks

DRUG

Placebo

Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.

Trial Locations (1)

75674

RECRUITING

GHU Saint Anne, Paris

Sponsors

Collaborators (1)

For Drug Consulting
All Listed Sponsors
collaborator

For Drug Consulting

OTHER

lead

Centre Hospitalier St Anne

OTHER

NCT05468073 - Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD | Biotech Hunter | Biotech Hunter